Dechra Pharmaceutcls - Directorate Change
27/11/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231127:nRSa6707Ua&default-theme=true
RNS Number : 6707U Dechra Pharmaceuticals PLC 27 November 2023
Monday, 27 November 2023
Dechra(®) Pharmaceuticals PLC
("Dechra" or "the Company")
Directorate Changes
Dechra announces that after 12 years' service with Dechra, Tony Griffin will
step down as an Executive Director of the Company with immediate effect. In
addition, Tony confirmed that he wishes to retire from his role as Managing
Director of DVP Europe, this will be effective as at 31 December 2023.
Consequently, as he is not now seeking re-election at the 2023 Annual General
Meeting, Resolution 7 contained in the Notice of Meeting, published on 14
November 2023 has been withdrawn.
Ian Page, Chief Executive Officer, Dechra said:
"I would like to take this opportunity to thank Tony for the significant
contribution that he has made to the Group during his tenure. Tony joined us
following the acquisition of Eurovet in 2013. This was a transformative
acquisition, providing critical mass, new markets, a wide range of
complementary products and additional expertise to our management team."
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com (mailto:corporate.enquiries@dechra.com)
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com (mailto:fiona@tooleystreet.com)
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related
products business. Our expertise is in the development, manufacture
marketing and sales of high quality products exclusively for veterinarians
worldwide. Dechra's business is unique as the majority of its products are
used to treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor products.
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain inside
information stipulated under the Market Abuse Regulation (EU) No. 596/2014.
Upon the publication of this announcement via the Regulatory Information
Service, this inside information is now considered to be in the public domain.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAPPGCUGUPWGAQ